

LEUKOCARE presenting at 12th Vaccine Congress in Budapest, Hungary

Several abstracts referring to LEUKOCARE' SPS[®] technology have been accepted for presentation at the 12th Vaccine Congress taking place September 16-19 in Budapest, Hungary.

Munich, Germany, 14 September 2018

Munich-based biotechnology company LEUKOCARE announced today that four abstracts featuring LEUKOCARE data and elaborated in close collaboration with different partners have been accepted for presentation at the 12th Vaccine Congress in Budapest. The presentations include data on stabilization of viral vectors, spray dried vaccine formulations, heat-stable vaccines and protective formulations for virus stability enhancement during low energy electron irradiation pathogen inactivation.

“We are pleased that such a large number of abstracts have been accepted at the 12th Vaccine Congress. This demonstrates our extensive scientific expertise in vaccine development and formulation of viral vectors” said Michael Scholl, Chief Executive Officer of LEUKOCARE. “Based on our proprietary SPS[®] formulation technology platform and in close collaborations with academia and industry, we are able to consistently improve the effectiveness of our technologies and to raise the awareness of formulation development not only from a commercial point of view but also from a scientific perspective.”

Following is a list of accepted abstracts featuring LEUKOCARE data at the 12th Vaccine Congress:

- 1) Low energy electron irradiation efficiently inactivates pathogens while preserving antigenic structures in protective formulation - a promising novel method for the generation of vaccines – Grunwald, T; Oral presentation; Wednesday, September 19
- 2) Effective Stabilization of Viral Vectors by Liquid and Lyophilized SPS[®] Formulations Adenovirus Serotype 5 as a Model – Reinauer, E; Poster presentation; Sunday, September 16
- 3) Development of a heat-stable MVA-based prime/boost vaccine against chronic hepatitis B – Sacherl, J.; Poster presentation; Sunday, September 16

4) Stability of dry powder vaccines – Scherließ, R.; Poster presentation;
Sunday, September 16

For more information on the poster sessions, please visit
<https://www.elsevier.com/events/conferences/vaccine-congress/program>.

About LEUKOCARE AG

LEUKOCARE provides a next-generation formulation technology platform for the protection of proteins like biopharmaceuticals to allow the development of better products. The proprietary Stabilizing and Protecting Solutions (SPS[®]) technologies are provided to development projects of partners in the pharmaceutical and medical device industry. LEUKOCARE's SPS[®] technologies improve stability and quality of biologics like antibodies, vaccines etc. in dry and liquid formulation including high-concentration formulations. SPS[®] technologies also protect proteins in biologically functionalized combination devices.

www.leukocare.com

Contact:

Michael Scholl

michael.scholl@leukocare.com

+49 (0) 89 7801 6650